NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 1763-1774

  Liu, Li Li ^a   Zhang, Mei Fang ^a   Pan, Ying Hua ^b   Yun, Jing Ping ^a   Zhang, Chris Zhiyi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Hepatocellular carcinoma; NORE1A; Prognosis; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; MESSENGER RNA; PROTEIN NORE1A; SORAFENIB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL VIABILITY; COLONY FORMATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84899102009     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1184-2     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
2. Chen WQ, Zheng RS, Zhang SW. Liver cancer incidence and mortality in China, 2009. Chin J Cancer. 2013;32(4):162-9. doi: 10.5732/cjc.013.10027.
3. Li XP, Cao GW, Sun Q, Yang C, Yan B, Zhang MY, et al. Cancer incidence and patient survival rates among residents in the Pudong New Area of Shanghai between 2002 and 2006. Chin J Cancer. 2012. doi: 10.5732/cjc.012.10200.
4. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5-S16.
5. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9(4):416-23. doi: 10.1038/nm843.
6. Zhang CZ, Cao Y, Yun JP, Chen GG, Lai PB. Increased expression of ZBP-89 and its prognostic significance in hepatocellular carcinoma. Histopathology. 2012;60(7):1114-24. doi: 10.1111/j.1365-2559.2011.04136.x.
7. Yun JP, Miao J, Chen GG, Tian QH, Zhang CQ, Xiang J, et al. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer. 2007;96(3):477-84. doi: 10.1038/sj.bjc.6603574.
8. Geli J, Kogner P, Lanner F, Natalishvili N, Juhlin C, Kiss N, et al. Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma. Int J Cancer. 2008;123(2):389-94. doi: 10.1002/ijc.23533.
9. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta. 2007;1776(1):58-85. doi: 10.1016/j.bbcan.2007.06.003.
10. Foukakis T, Au AY, Wallin G, Geli J, Forsberg L, Clifton-Bligh R, et al. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion. J Clin Endocrinol Metab. 2006;91(3):1143-9. doi: 10.1210/jc.2005-1372.
11. Vavvas D, Li X, Avruch J, Zhang XF. Identification of Nore1 as a potential Ras effector. J Biol Chem. 1998;273(10):5439-42.
12. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene. 2002;21(9):1381-90. doi: 10.1038/sj.onc.1205192.
13. Moshnikova A, Kuznetsov S, Khokhlatchev AV. Interaction of the growth and tumour suppressor NORE1A with microtubules is not required for its growth-suppressive function. BMC Res Notes. 2008;1:13. doi: 10.1186/1756-0500-1- 13.
14. Shinmura K, Tao H, Nagura K, Goto M, Matsuura S, Mochizuki T, et al. Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma. Lung Cancer. 2011;71(1):19-27. doi: 10.1016/j.lungcan.2010.04.006.
15. Hesson L, Dallol A, Minna JD, Maher ER, Latif F. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene. 2003;22(6):947-54. doi: 10.1038/sj.onc.1206191.
16. Irimia M, Fraga MF, Sanchez-Cespedes M, Esteller M. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene. 2004;23(53):8695-9. doi: 10.1038/sj.onc.1207914.
17. Lorente A, Mueller W, Urdangarin E, Lazcoz P, Lass U, von Deimling A, et al. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol. 2009;19(2):279-92. doi: 10.1111/j.1750-3639.2008.00185.x.
18. Calvisi DF, Donninger H, Vos MD, Birrer MJ, Gordon L, Leaner V, et al. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res. 2009;69(11):4629-37. doi: 10.1158/0008-5472.CAN-08-3672.
19. Park SJ, Lee D, Choi CY, Ryu SY. Induction of apoptosis by NORE1A in a manner dependent on its nuclear export. Biochem Biophys Res Commun. 2008;368(1):56-61. doi: 10.1016/j.bbrc.2008.01.044.
20. Park J, Kang SI, Lee SY, Zhang XF, Kim MS, Beers LF, et al. Tumor suppressor ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis. J Biol Chem. 2010;285(45):35029-38. doi: 10.1074/jbc.M110.165506.
21. Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol. 2012;83(9):1278-89. doi: 10.1016/j.bcp.2012.02.002.
22. Tommasi S, Dammann R, Jin SG, Zhang XF, Avruch J, Pfeifer GP. RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene. 2002;21(17):2713-20. doi: 10.1038/sj.onc. 1205365.
23. Lee CK, Lee JH, Lee MG, Jeong SI, Ha TK, Kang MJ, et al. Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors. BMC Cancer. 2010;10:577. doi: 10.1186/1471-2407-10-577.
24. Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, Zhang H, et al. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest. 2005;85(9):1065-75. doi: 10.1038/labinvest.3700306.
25. Macheiner D, Heller G, Kappel S, Bichler C, Stattner S, Ziegler B, et al. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J Hepatol. 2006;45(1):81-9. doi: 10.1016/j.jhep.2005. 12.017.
26. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51(4):725-33. doi: 10.1016/j.jhep.2009.03.028.
27. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130(4):1117-28. doi: 10.1053/j.gastro.2006.01.006.
28. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817-26. doi: 10.1016/S1470-2045(12) 70233-4.
29. Zhang CZ, Liu L, Cai M, Pan Y, Fu J, Cao Y, et al. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One. 2012;7(12):e51703. doi: 10.1371/journal. pone.0051703.
30. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012;56(6):2242-54. doi: 10.1002/hep.25907.
31. Huang XY, Ke AW, Shi GM, Zhang X, Zhang C, Shi YH, et al. alphaB-Crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology. 2013. doi: 10.1002/hep.26255.
32. Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, et al. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol. 2012;57(1):108-15. doi: 10.1016/j.jhep.2012.02.019.
33. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009;16(5):425-38. doi: 10.1016/j.ccr.2009.09.026.
34. Fujimaki S, Matsuda Y, Wakai T, Sanpei A, Kubota M, Takamura M, et al. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Lett. 2012;319(1):98-108. doi: 10.1016/j.canlet.2011.12.043.
35. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol. 2010;52(1):88-95. doi: 10.1016/j.jhep.2009.10.011.